Sarcoidosis: patient treatment priorities
| Autor: | Jeanette Boyd, Jack Richardson, Robert P. Baughman, Johann Hochreiter, Ginger Spitzer, Dominique Valeyre, Rita Barriuso, Chris Knoet, Filippo Martone, Gianluca Ziosi, Bernd Quadder, Kelli Beyer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty business.industry Original Research Letters lcsh:R MEDLINE lcsh:Medicine medicine.disease 03 medical and health sciences 0302 clinical medicine 030228 respiratory system Multidisciplinary approach medicine Patient treatment Patient survey 030212 general & internal medicine Sarcoidosis business Intensive care medicine |
| Zdroj: | ERJ Open Research, Vol 4, Iss 4 (2018) ERJ Open Research |
| ISSN: | 2312-0541 |
| Popis: | Sarcoidosis is a rare disease with the number of patients in the European Union (28 member states), Norway, Iceland and Lichtenstein estimated as ∼102 000 [1, 2]. Some 40% of individuals experience sarcoidosis as a chronic condition, while >60% of individuals find that the disease resolves within 2–5 years [3]. However, it has been shown that patients can still have symptoms that result in a reduced quality of life (QoL) even after clinical signs of disease have disappeared. These symptoms include fatigue, pain, everyday cognitive failure, small fibre neuropathy, exercise limitation and depressive symptoms [4, 5]. Findings from a recent survey of patients and their partners in the Netherlands also showed that sarcoidosis has a significant impact on their lives [6]. Sarcoidosis patient survey reveals QoL and functionality are required as core outcomes in treatment and care, along with more multidisciplinary working by clinicians and the establishment of specialist sarcoidosis centres in every European country http://ow.ly/DTvt30mQnqc |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|